ESR1 and breast cancer: IHC demonstrated positivity for GATA3, ER (60%) and PR (2%), with HER2 negativity and a high proliferation index (Ki-67 70%) (Figures 2D-H), findings concordant with the patient’s previous diagnosis of Luminal B, HER2-negative breast cancer.